Inflammation-related cancer or cancer-related inflammation

Year 2018, Volume: 4 Issue: 1, 1 - 5, 04.01.2018

Shrihari T.g

https://doi.org/10.18621/eurj.312327

Cited By: 2

Abstract

Inflammation
is the body’s defensive action against various stimuli such as physical or
chemical or infectious agents. Acute inflammation and their mediators help in
tissue repair and healing. If the inflammation aggravates chronically,
non-resolved, dysregulated immune system, results release of various inflammatory
mediators such as free radicals (ROS and RNS), cytokines, chemokines, growth
factors and proteolytic enzymes produced by innate and adaptive immune cells
activate transcriptional factors (NF-KB,STAT3 and HIF-1α) results in cell
proliferation, angiogenesis, immunosuppression, genetic instability, invasion
and metastasis. Oncogenes related to cancer activate inflammatory mediators
such as chemokines and cytokines, which alters the inflammatory tumor microenvironment,
promotes tumor progression. This article highlights about the role of
inflammation and oncogenes activate inflammatory mediators in tumor
progression.

Keywords

Inflammation, cancer, lymphocytes, NF-KB, STAT3, myeloid-derived suppressor cells, inflammatory mediators, tumor associated macrophages, tumor associated neutrophils, HIF-1α, oncogenes, cytokines, chemokines, growth factors, COX-2

References

• [1] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010;140:883-99.
• [2] Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015;125:3347-55.
• [3] Maciel TT, Moura IC, Hermine O. The role of mast cells in cancers. F1000Prime Rep 2015;7:9.
• [4] Shrihari TG. Dual role of inflammatory mediators in cancer. Ecancermedicalscience 2017;11:721.
• [5] Korniluk A, Koper O, Kemona H, Dymicka-Piekarska V. From inflammation to cancer. Ir J Med Sci 2017:186;57-62.
• [6] Okada F. Inflammation-related carcinogenesis: current findings epidemiological trends, causes and mechanisms. Yonago Acta Medica 2014:57:65-72.
• [7] Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015;347:78-81.
• [8] Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res 2011;317:664-73.
• [9] Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073-81.
• [10] Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
• [11] Chai EZ, Siveen KS, Shanmugam MK, Arfuso F, Sethi G. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem J 2015;468:1-15.
• [12] Katoh H, Watanabe M. Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediators Inflamm 2015;2015:159269.
• [13] Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014;41:49-61.
• [14] Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer 2014;110:469-78.
• [15] Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating ntigen-presenting cells critical for T cell immunity. Cancer Cell 2014;26:638-52.
• [16] Houghton AM. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 2010;9:1732-7.
• [17] Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013;24:257-71.
• [18] Necula LG, Chivu-Economescu M, Stanciulescu EL, Bleotu C, Dima SO, Alexiu I, et al. IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits. J Gastrointestin Liver Dis 2012;21:23-9.
• [19] Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13.
• [20] Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101-14.
• [21] Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
• [22] Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 2014;14:768-74.
• [23] Candido J. Cancer-related inflammation .J Clin Immuno 2013;33:579-84.
• [24] Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
• [25] Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol 2015;33:445-74.
• [26] Yang L, Pang Y, Moses HL. TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010;31:220-7.
• [27] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
• [28] Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241.
• [29] Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer 2012;12:307-13.
• [30] Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116.
• [31] Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015;15:73-86.
• [32] Castello G, Scala S, Palmieri G, Curley SA, Izzo F. HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. Clin Immunol 2010;134:237-50.
• [33] Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010;22:223-30.
• [34] Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011;470:548-53.
• [35] Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 2013;210:2435-66.
• [36] Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, et al. IL-17-producing γΔ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 2015;522:345-8.
• [37] Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, et al. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 2015;348:136-9.
• [38] Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008;27:5932-43.
• [39] Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014;41:14-20.
• [40] Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010;24:241-55.
• [41] Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
• [42] Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013;218:1402-10.
• [43] Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 2015;75:5-10.
• [44] Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71.
• [45] Chaudhry A, Rudensky AY. Control of inflammation by integration of environmental cues by regulatory T cells. J Clin Invest 2013;123:939-44.
• [46] Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol 2015;16:343-53.
• [47] Ohnishi S, Ma N, Thanam R, Pinlaor S, Hammam O, Murata M, Kawanishi S. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med Cell Longev 2013;2013:387014.
• [48] Diakos C I, Charles CA, Mcmillan DC, Clarke SJ. Cancer related inflammation and treatment effectives. Lancet Oncol 2014;15:493-503.
• [49] Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 2014;41:1052-63.
• [50] Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012;22:33-40.
• [51] Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014;2014:149185.
• [52] Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in tumor microenvironment: expect the unexpected. J Clin Invest 2015;125:3356-64.
• [53] Condamine T, Gabrilovich DI. Can the suppressive activity of myeloid-derived suppressor cells be “chop”ped? Immunity 2014;41:341-2.
• [54] Shrihari TG. Inflammation related cancer-Highlights. J Carcinog Mutagen 2016;7:269.